619 related articles for article (PubMed ID: 7332791)
1. [Breast cancer and use of antihypertensive drugs and oral contraceptives: results of a case-control study (author's transl)].
Clavel F; Lê M; Laplanche A
Bull Cancer; 1981; 68(5):449-55. PubMed ID: 7332791
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and their relationship to cancer of the breast: a medicolegal problem.
Clasper RK
Leg Med Annu; 1977; ():297-313. PubMed ID: 593041
[No Abstract] [Full Text] [Related]
3. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
4. [Effects of hormonal contraception on benign changes of the breast].
De Cecco L; Ragni N; Boccardo E; Viglino S
Minerva Ginecol; 1982 Nov; 34(11):889-94. PubMed ID: 6818496
[No Abstract] [Full Text] [Related]
5. [Incidence of arterial hypertension in women taking oral hormonal contraceptive agents (femigen)].
Mikrut W
Wiad Lek; 1983 Oct; 36(19):1587-92. PubMed ID: 6198806
[TBL] [Abstract][Full Text] [Related]
6. [Amenorrhea after hormonal contraception. Prophylaxis, findings and therapy].
Kunz J
Gynakol Rundsch; 1976; 16(1):47-64. PubMed ID: 986984
[No Abstract] [Full Text] [Related]
7. [Effects of hormonal contraceptives on the female breast (author's transl)].
Tapia JE; Mall-Haefeli M
Schweiz Rundsch Med Prax; 1977 Feb; 66(8):223-6. PubMed ID: 557204
[No Abstract] [Full Text] [Related]
8. [Oral contraceptives and risk of benign tumors of the breast: recent data from the literature].
Simard A
Union Med Can; 1977 Aug; 106(8):1115-9. PubMed ID: 333686
[TBL] [Abstract][Full Text] [Related]
9. [Real and seeming side-effects of oral contraceptives with an emphasis on medical and haematological problems. Review of literature (author's transl)].
Bucher U; Kägi M; Beck EA
Schweiz Rundsch Med Prax; 1976 May; 65(19):570-80. PubMed ID: 790374
[TBL] [Abstract][Full Text] [Related]
10. [Study of oral contraceptives action on blood folate levels (author's transl)].
Karlin R; Bourgeay M
Pathol Biol (Paris); 1976 Apr; 24(4):251-5. PubMed ID: 778757
[TBL] [Abstract][Full Text] [Related]
11. Oral contraceptive use and other risk factors in relation to HER-2/neu overexpression in breast cancer among young women.
Gammon MD; Hibshoosh H; Terry MB; Bose S; Schoenberg JB; Brinton LA; Bernstein JL; Thompson WD
Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):413-9. PubMed ID: 10350436
[TBL] [Abstract][Full Text] [Related]
12. [Behaviour of ujoviridin exposure test (ICG) in conjunction with application of hormonal contraceptives (author's transl)].
Brügmann E; Göretzlehner G
Zentralbl Gynakol; 1981; 103(14):823-6. PubMed ID: 7293553
[TBL] [Abstract][Full Text] [Related]
13. Case-control study of antihypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program.
Williams RR; Feinleib M; Connor RJ; Stegens NL
J Natl Cancer Inst; 1978 Aug; 61(2):327-35. PubMed ID: 277719
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives and breast cancer.
Johnson KH; Millard PS
J Fam Pract; 1996 Oct; 43(4):340-1. PubMed ID: 8874363
[TBL] [Abstract][Full Text] [Related]
15. [Oral contraception and cancer risk].
Genton CY
Schweiz Med Wochenschr; 1981 Nov; 111(46):1742-8. PubMed ID: 6274005
[TBL] [Abstract][Full Text] [Related]
16. [Oral contraceptives and breast cancer].
Zoricić D; Ambrozić B; Perić D
Lijec Vjesn; 1998 Dec; 120(12):392-7. PubMed ID: 19658362
[TBL] [Abstract][Full Text] [Related]
17. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer and oral contraceptives: critique of the proposition that high potency progestogen products confer excess risk.
Sturtevant FM
Biomed Pharmacother; 1984; 38(8):371-9. PubMed ID: 6525434
[TBL] [Abstract][Full Text] [Related]
19. Risks of oral contraceptive use in women over 35.
Stenchever MA
J Reprod Med; 1993 Dec; 38(12 Suppl):1030-5. PubMed ID: 8120860
[TBL] [Abstract][Full Text] [Related]
20. [Effect of combined hormonal oral contraceptives on several body systems].
Simeonova L
Akush Ginekol (Sofiia); 1976; 15(3):220-2. PubMed ID: 998936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
